Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 7/20 | 0.65 |
| ▸ | TACR1 | P25103 | 2/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12563610 | 1.00 | OPRL1 (0.65) | OPRL1TACR1HTR1DALDH1A1CCR1 | |
| Hydrochloric Acid SCHEMBL11075754 | 0.78 | OPRL1 (1.00) | OPRL1TACR1KDM1AMAOBOPRM1 | |
| SCHEMBL14549659 | 0.78 | OPRL1 (0.60) | OPRL1TACR1KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL14482843 | 0.77 | OPRL1 (0.61) | OPRL1TACR1KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL14482780 | 0.77 | OPRL1 (0.61) | OPRL1TACR1KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL14482782 | 0.77 | OPRL1 (0.61) | OPRL1TACR1KDM1AMAOB | |
| SCHEMBL1255944 | 0.75 | OPRL1 (0.52) | OPRL1ALDH1A1OPRM1OPRD1OPRK1 | |
| SCHEMBL23269635 | 0.75 | CCR1 (0.53) | OPRL1CCR1OPRM1OPRD1OPRK1 | |
| SCHEMBL14881788 | 0.74 | OPRL1 (0.56) | OPRL1TACR1ALDH1A1KDM1AMAOB | |
| SCHEMBL14881787 | 0.74 | OPRL1 (0.56) | OPRL1TACR1ALDH1A1KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136820-A1 | Heterocyclic Compounds as CCR2 Antagonists | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136820-A1 | Heterocyclic Compounds as CCR2 Antagonists | CCR2, CCR3, CXCR2 | OPRL1 34/4885TACR1 75/4885HTR1D 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.